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Hydrogels are three-dimensional, cross-linked networks of
water-soluble polymers. Hydrogels can be made from virtually
any water-soluble polymer, encompassing a wide range of
chemical compositions and bulk physical properties. Further-
more, hydrogels can be formulated in a variety of physical
forms, including slabs, microparticles, nanoparticles, coatings,
and films. As a result, hydrogels are commonly used in clinical
practice and experimental medicine for a wide range of appli-
cations, including tissue engineering and regenerative
medicine [1], diagnostics [2], cellular immobilization [3],Abbreviations: PEG, poly(ethylene glycol); PEO, poly(ethylene oxide);
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butylacrylamide.
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Open access under CC BY-NC-ND license.separation of biomolecules or cells [4], and barrier materials
to regulate biological adhesions [5].
The unique physical properties of hydrogels have sparked
particular interest in their use in drug delivery applications.
Their highly porous structure can easily be tuned by control-
ling the density of cross-links in the gel matrix and the affinity
of the hydrogels for the aqueous environment in which they
are swollen. Their porosity also permits loading of drugs
into the gel matrix and subsequent drug release at a rate depen-
dent on the diffusion coefficient of the small molecule or mac-
romolecule through the gel network. Indeed, the benefits of
hydrogels for drug delivery may be largely pharmacokinetic e
specifically that a depot formulation is created from which
drugs slowly elute, maintaining a high local concentration of
drug in the surrounding tissues over an extended period, al-
though they can also be used for systemic delivery. Hydrogels
are also generally highly biocompatible, as reflected in their
successful use in the peritoneum [6] and other sites in vivo.
Biocompatibility is promoted by the high water content of
hydrogels and the physiochemical similarity of hydrogels to
the native extracellular matrix, both compositionally (particularly
in the case of carbohydrate-based hydrogels) and mechanically.
Biodegradability or dissolution may be designed into hydrogels
via enzymatic, hydrolytic, or environmental (e.g. pH,
Fig. 1. Mechanism of in situ physical gelation driven by hydrophobic
interactions.
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is not always desirable depending on the time scale and loca-
tion of the drug delivery device. Hydrogels are also relatively
deformable and can conform to the shape of the surface to
which they are applied. In the latter context, the muco- or bio-
adhesive properties of some hydrogels can be advantageous in
immobilizing them at the site of application or in applying
them on surfaces that are not horizontal.
Despite these many advantageous properties, hydrogels also
have several limitations. The low tensile strength of many
hydrogels limits their use in load-bearing applications and
can result in the premature dissolution or flow away of the
hydrogel from a targeted local site. This limitation may not
be important in many typical drug delivery applications (e.g.
subcutaneous injection). More important, perhaps, are prob-
lems relating to the drug delivery properties of hydrogels.
The quantity and homogeneity of drug loading into hydrogels
may be limited, particularly in the case of hydrophobic drugs.
The high water content and large pore sizes of most hydrogels
often result in relatively rapid drug release, over a few hours
to a few days. Ease of application can also be problematic;
although some hydrogels are sufficiently deformable to be
injectable, many are not, necessitating surgical implantation.
Each of these issues significantly restricts the practical use of
hydrogel-based drug delivery therapies in the clinic.
In this review, we focus on recent developments addressing
three key clinically relevant issues regarding the use of hydro-
gels for drug delivery: facilitating the in vivo application of
drug-eluting hydrogels, extending their duration of drug re-
lease, and broadening the range of drugs which they effec-
tively deliver.
2. Improving the delivery of hydrogels
Hydrogels used in drug delivery are usually formed outside
of the body and impregnated with drugs before placement of
the hydrogeledrug complex in the body. A wide range of
cross-linking strategies can be used, including UV photopoly-
merization and various chemical cross-linking techniques.
Such cross-linking methods are useful only if toxic reagents
can be completely removed prior to hydrogel implantation,
which may be difficult to achieve without also leaching loaded
drug out of the hydrogel. The main disadvantage of such ap-
proaches is that the preformed material must be implanted,
since bulk hydrogels have a defined dimensionality and often
high elasticity which generally excludes their extrusion
through a needle. The latter problem can sometimes be cir-
cumvented by making the preformed gel into micro- or nano-
particles. In some applications, the hydrogels can also be
formed in situ (i.e. in vivo), although one then has to consider
the potential risks of exposure to UV irradiation (and the need
for additional equipment) or to cross-linking chemicals.
As an alternative, non-cross-linked linear polymers can be
used as the drug delivery vehicle. In general, the rate of
drug release from a linear polymer matrix is inversely propor-
tional to its viscosity [7]. However, it may be difficult or
impossible to dissolve the polymer(s) of interest to a highenough concentration to control the rate of drug release to
the extent desired. Even if that were possible, the yield stress
of the resulting material may be so high that injection is im-
possible, or the viscosity may be so high that resistance to
flow in a narrow and/or long extrusion device (needle, laparo-
scope) is prohibitive, as described by Poiseuille’s equation.
Furthermore, unless the water-soluble polymer chains are
somehow cross-linked, they swell and subsequently dissolve
in the aqueous in vivo environment, sometimes within a few
hours for highly hydrophilic polymers. Because of these con-
siderations, there has been considerable interest in formula-
tions which exhibit the properties of linear polymer
solutions outside of the body (allowing easy injection) but
gel in situ within the body, providing prolonged drug release
profiles. Both physical and chemical cross-linking strategies
have been pursued to achieve in situ gelation.2.1. Physically cross-linked hydrogelsPhysical cross-linking of polymer chains can be achieved
using a variety of environmental triggers (pH, temperature,
ionic strength) and a variety of physicochemical interactions
(hydrophobic interactions, charge condensation, hydrogen
bonding, stereocomplexation, or supramolecular chemistry).
2.1.1. Hydrophobic interactions
Polymers with hydrophobic domains can cross-link in
aqueous environments via reverse thermal gelation, also
known as ‘solegel’ chemistry. Polymers (or oligomers) with
such gelation properties are referred to as gelators and are typ-
ically moderately hydrophobic. Hydrophobicity-driven gela-
tion often occurs via the mechanism shown in Fig. 1. A
gelator (the hydrophobic segment) is coupled to a hydrophilic
polymer segment by post-polymerization grafting or by
directly synthesizing a block copolymer to create a polymer
amphiphile. Such amphiphiles are water soluble at low tem-
perature. However, as the temperature is increased, hydropho-
bic domains aggregate to minimize the hydrophobic surface
area contacting the bulk water, reducing the amount of struc-
tured water surrounding the hydrophobic domains and maxi-
mizing the solvent entropy. The temperature at which
gelation occurs depends on the concentration of the polymer,
the length of the hydrophobic block, and the chemical struc-
ture of the polymer: the more hydrophobic the segment, the
larger the entropic cost of water structuring, the larger the
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gelation temperature.
The chemical structures of some common hydrophobic
blocks which can undergo reverse thermal gelation at or
near physiological temperature are shown in Fig. 2. Triblock
copolymers of poly(ethylene oxide)epoly(propylene oxide)e
poly(ethylene oxide) (PEOePPOePEO, the poloxamers/
Pluronics) are the most widely used reverse thermal gelation
polymers [8]. At a concentration of 25% (w/v), an aqueous so-
lution of poloxamer 407, a PEOePPOePEO triblock copoly-
mer containing w101 repeat units in each of the PEO blocks
and w56 repeat units in the PPO block, is a viscous liquid at
room temperature or below but forms a hydrogel at body tem-
perature (37 C) which is sufficiently gel-like to hold its shape
in an inverted test-tube. Poloxamer 407 has been used to ex-
tend the duration of lidocaine release [9,10]. The drug was for-
mulated in the polymer solution at a cool temperature and then
injected at the sciatic nerve in rats, where body temperature
caused gelation, resulting in a marked prolongation of nerve
blockade. However, it is instructive to compare the several
hours duration of drug release/nerve blockade achieved with
poloxamer to the days- to weeks-long duration nerve blockade
that can be achieved with some microparticle-based systems
[11]. In addition to the relatively rapid diffusion of drugs out
of the hydrophilic gel matrix [9], the maximum duration of
drug release is limited by the influx of water which dilutes
the polymer below its critical gelation concentration such
that the matrix loses gel-like properties. We have seen this
happen within a small number of hours after intraperitoneal
injection of concentrated solutions of poloxamer 407.
The rapid dissolution or dissipation of such copolymers in
vivo can be overcome by covalent-cross-linking. For example,
in ethoxysilane-capped PEOePPOePEO triblocks, the ethoxy-
silane groups hydrolyze over time to form silanol groupsFig. 2. Chemical structures and abbreviations of common thermowhich covalently cross-link, preventing the rapid dilution of
the polymer with water in vivo [12]. Alternately, an amine-ter-
minated poloxamer can be grafted with carbohydrates such as
hyaluronic acid to form self-assembled carbohydrate-rich net-
works which slow down release of small-molecule drugs such
as ciprofloxacin [13] and biomolecular drugs such as human
growth hormone [14]. Carbohydrate grafting to poloxamers re-
duces the critical gelation concentration and the dissolution
rate of the networks in vivo because of the high viscosity of
the hyaluronic acid grafts. Poloxamers can also be modified
by adding an additional polymer block at each chain terminus,
forming an ABCBA pentablock copolymer with improved
properties for drug delivery. For example, pentablock
PDMAEMAePEOePPOePEOePDMAEMA forms free-
flowing liquids at room temperature but forms elastic hydro-
gels at concentrations above 12% when heated, facilitating
the near zero-order release of sparingly soluble drugs [15].
Other types of multi-block amphiphiles (i.e. polymers with
both hydrophilic and hydrophobic domains) have been
synthesized using a wide range of polymers. Triblock (ABA)
copolymers containing biodegradable poly(L-lactic acid),
poly(L-glycolic acid), or copolymers thereof are the most
common alternative to poloxamer-based copolymers. The hy-
drophobic block may be contained as the center (B) block (e.g.
PEGePLGAePEG [16]) or in the arm (A) blocks (e.g.
PLGAePEGePLGA [17,18]). PL(G)A-based gelators typi-
cally exhibit better biodegradability, higher gelation tempera-
tures (permitting easier handling pre-injection), and longer
periods of sustained drug release compared to poloxamer
systems [19]. Release of hydrophilic compounds from
PLGAePEGePLGA copolymers was found to be diffusion-
controlled, while release of hydrophobic compounds showed
an initial diffusion-controlled stage followed by a prolonged
polymer degradation-controlled stage [19]. Asymmetric ABCgelling hydrophobic blocks; R ¼ any thermogelling polymer.
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tionalities within the thermally induced gel. For example, tri-
block copolymers of PEG, PLA, and poly(L-glutamic acid)
have been synthesized which can permit selective modification
of the L-glutamic acid block with specific targeting groups
such as the cell-adhesive RGD peptide [20].
A range of other synthetic thermally gelling polymers have
also been investigated to further prolong drug release or re-
duce the concentration at which gelation occurs. Poly(N-iso-
propylacrylamide) (PNIPAM) is one of the most widely
studied thermoresponsive polymers. PNIPAMepoly(phos-
phorylcholine)ePNIPAM triblock copolymers have been
reported which form gels at 6e7 wt% when the phase transi-
tion temperature of the PNIPAM arms (w32 C) is exceeded
[21]. Grafting PNIPAM linear chains onto natural polymers
can also convert those polymers into physically cross-linkable
hydrogels. For example, PNIPAM-grafted hyaluronic acid
formed a gel in vivo which showed a burst release of riboflavin
for 12 h and sustained release thereafter [22]; NIPAM-grafted
chitosan has also been used to control the release of 5-fluoro-
uracil [23]. Polycaprolactone (PCL) homopolymers or copoly-
mers with glycolic acid [24] have also been combined with
poly(ethylene glycol) in both triblock [25] and diblock [26]
forms to facilitate prolonged release. Diblock PEGePCL
polymers facilitated the release of FITC-labeled bovine serum
albumin over a period of 30 days owing to the lower water
content and longer network stabilities of PEGePCL copoly-
mers compared to poloxamers and other common physical
gelators [26].
Other types of synthetic thermally gelling polymers have
been used, increasing the range of chemical functionalities
which can be incorporated into the hydrophobic block. Poly-
(organophosphazenes) can produce mechanically strong gels
at concentrations below 15 wt% polymer and permit the intro-
duction of various hydrophobic, hydrophilic, or other func-
tional substituents into the polymer backbone to modify the
mechanical properties of the hydrogel, the gel degradation
rate, and the polymeredrug affinity [27]. Doxorubicin was re-
leased over a period of 1 month from a poly(organophospha-
zene) containing structured hydrophobic, hydrophilic, and
biodegradable domains [28]. Polyurethanes [29] or poly(ether
ester urethanes) [30] can also be used to impart a wide range
of functionalities into the polymer backbone. The double bond
in the polymer backbone of poly(propylene fumarate) (PPF)
can be used to subsequently polymerize the physically cross-
linked gels formed from block copolymers of PPF and/or
copolymerize other types of vinyl monomers into the gel to
further modify the gel properties. Block copolymers of PPF
with methoxy poly(ethylene glycol) undergo reverse thermal
gelation at temperatures between 30 and 75 C at concentra-
tions as low as 5 wt% [31].
Some natural polymers also undergo reverse thermal gela-
tion. Chitosan solutions containing glycerol-2-phosphate gel at
a temperature close to 37 C [32], and a solution of chitosan
grafted with 40 wt% PEG gels at 37 C, releasing bovine se-
rum albumin over 70 h after an initial burst release [33].
Similar thermally triggered transitions have also beendemonstrated with hydroxypropylcellulose [34,35] and meth-
ylcellulose [36].
Changes in the morphology of the gelator can also tune the
physical and pharmacokinetic properties of physically cross-
linked gels. For example, star diblock copolymers can be pro-
duced from multi-functional controlled radical polymerization
initiators to form highly efficient thermally gelling polymers.
Star diblocks are typically prepared by first polymerizing a wa-
ter-soluble polymer in the center of the star (e.g. phosphoryl-
cholines) followed by a thermosensitive (e.g. poly(propylene
oxide) methacrylate) or pH-sensitive (e.g. 2-diisopropylami-
noethyl methacrylate) gelator in the outer arms [37]. The ad-
vantage of such polymer architectures is that lower polymer
concentrations are required to achieve strongly gelled systems.
Formulating thermogelling polymers as particles can also sig-
nificantly lower the polymer fraction required to form gels due
to long-range electrostatic double layer interactions between
the surfaces of the particles. For example, biocompatible inter-
penetrating polymer network microgels comprising poly(N-
isopropylacrylamide) and polyacrylic acid undergo reversible
gelation to form particle assemblies at 33 C at weight concen-
trations above 2.5 wt% and can control the release of loaded
dextran markers [38]. This critical concentration is approxi-
mately one order of magnitude lower than that observed for
conventional poloxamer systems.
Several other types of low molecular weight gelators have
been investigated, many of which may be suitable for drug de-
livery applications [39]. Different gelators can be used to
achieve gelation at different concentrations or time scales, to
tune the mechanical strength of the injectable hydrogels,
and/or to control the release kinetics by optimizing interac-
tions between the hydrogel and a target drug. The mechanical
strength required from a drug-releasing hydrogel depends on
the specific location and use of the hydrogel in the body, for
example, whether or not the hydrogel is intended for a high-
stress field (such as at a weight-bearing joint). The correlation
between drug release properties and mechanical strength
remains somewhat unclear.
2.1.2. Charge interactions
Charge interactions have been widely investigated for
cross-linking in situ gelling polymers. One advantage of this
approach is that biodegradation can occur as ionic species in
extracellular fluid bind competitively with the gel components,
breaking down the cross-linked network. Cross-linking (or de-
cross-linking) can also be triggered by pH changes which ion-
ize or protonate the ionic functional groups that cause gelation,
in some cases enabling the delivery of the liquid-like gel pre-
cursors in a single syringe.
Charge interactions may occur between a polymer and
a small molecule or between two polymers of opposite charge
to form a hydrogel, as illustrated in Fig. 3. As an example of
small-molecule cross-linking, elastin-like polypeptides have
been cross-linked via electrostatic interactions between their
cationic lysine residues and anionic organophosphorus cross-
linkers under physiological conditions [40]. As examples of
polymerepolymer cross-linking, ionic-complementary
Fig. 3. Mechanisms of in situ physical gelation based on charge interactions
with an oppositely-charged polymer or an oppositely-charged small molecule
cross-linker.
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can self-assemble to form hydrogels in situ [41], and a mixture
of quaternized chitosan and glycerophosphate forms an opti-
cally clear, ionically cross-linked gel at physiological temper-
ature which can release doxorubicin hydrochloride as
a function of pH [42]. Charge interactions can also be used
to cross-link microparticle or nanoparticle gels to create
three-dimensional particle assemblies with favorable drug de-
livery properties. For example, dextran microspheres coated
with anionic and cationic polymers exhibit spontaneous gela-
tion upon mixing due to ionic complex formation between the
oppositely charged microparticles [43].
2.1.3. Hydrogen bonding interactions
Hydrogen bonding interactions can be used to produce
hydrogels in vitro by freeze-thawing, e.g. in the formulation
of poly(vinyl alcohol)-based hydrogels [44]. Hydrogen bonding
can also be used to formulate injectable hydrogels. Mixtures of
two or more natural polymers can display rheological syner-
gism, meaning that the viscoelastic properties of the polymer
blends are more gel-like than those of the constituent polymersFig. 4. In situ physical gelation via hydrogen bonding interactions between geom
hydrogen bonds break under shear.measured individually [45]. This synergism is typically a result
of hydrogen bonding interactions between the polymer chains
facilitated by the compatible geometries of the interacting poly-
mers, as illustrated in Fig. 4. Shearing the mixture (i.e. forcing
the blend through a needle) can disrupt these relatively weak
hydrogen bonds, facilitating injection. Blends of natural poly-
mers such as gelatineagar [46], starchecarboxymethyl cellu-
lose [47], and hyaluronic acidemethylcellulose [48] form
physically cross-linked gel-like structures which are injectable.
Such blends generally exhibit excellent biocompatibility due to
the absence of chemical cross-linkers and because the formula-
tions are typically based on or resemble extracellular matrix
polymers. However, hydrogen-bonded networks can dilute
and disperse over a few hours in vivo due to influx of water,
restricting their use to relatively short-acting drug release
systems unless some other form of cross-linking is also used.
2.1.4. Stereocomplexation
Stereocomplexation refers to synergistic interactions which
can occur between polymer chains or small molecules of the
same chemical composition but different stereochemistry. Of
particular relevance, in situ forming hydrogels with high stor-
age moduli (up to 14 kPa) can be prepared by exploiting the
strong interaction between polylactide blocks with L- and D-
stereochemistry [49], as illustrated schematically in Fig. 5.
Multi-arm PEGePLA dendrimers or star diblock copolymers
can be cross-linked using this stereospecific interaction to
form hydrogels with transition temperatures ranging from 10
to 70 C depending on the polymer concentration and PLA
block length [50]. Natural polymers can also be cross-linked
via stereocomplexing grafts. Grafting L-lactide and D-lactide
oligomers to dextran precursors induces spontaneous gelation
in water [51e53], resulting in excellent biocompatibility and
biodegradability [53] without requiring the use of harsh/dena-
turing conditions such as organic solvents, chemical cross-
linkers, or the formation of hydrophobic domains which may
denature embedded proteins. One significant limitation of ster-
eocomplexation is the relatively restricted range of polymeretrically-compatible biopolymers (methylcellulose and hyaluronic acid); the
Fig. 5. Mechanism of in situ physical gelation via stereocomplexation between
L- and D- lactide polymer chains.
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stoichiometry or otherwise changing the composition of mat-
ter within the lactate gelators can significantly weaken or
altogether eliminate the stereochemical interaction.
2.1.5. Supramolecular chemistry
A newer approach to form hydrogels in situ involves using
specific molecular recognition motifs and/or supramolecular
chemistry (i.e. the ordered arrangement of molecules into de-
fined structures). The most common type of cross-linking
interaction in this category is the formation of inclusion
complexes between poly(alkylene oxide) polymers and cyclo-
dextrins [54], as illustrated in Fig. 6. Cyclodextrins are mole-
cules which have hydrophilic surfaces but hydrophobic
pockets which are geometrically compatible with poly-
(alkylene oxide)-based polymers such as PEO or PPO. For
example, poly(ethylene oxide)-based hydrogels can be cross-
linked using alpha-cyclodextrin to form a reversible hydrogel
which can be injected through a needle [55,56]. Similarly,
beta-cyclodextrin can be used to gel poly(propylene oxide)-
grafted dextran into a hydrogel [57]. Self-assembled systems
have also been reported that apply both hydrophobic interac-
tions and supermolecular chemistry to facilitate the formation
of denser and/or more stable hydrogel networks. PEOe
poly(R-3-hydroxybutyrate) (PHB)ePEO triblock copolymers
were complexed with alpha-cyclodextrin to form strongFig. 6. Mechanism of in situ physical gelation via the formation of a supramhydrogel networks cross-linked both by the thermal gelation
of the hydrophobic PHB segments and by the inclusion com-
plexes formed between the PEO segments and cyclodextrin;
this system can release FITCedextran for up to 1 month [58].
Recognition between naturally occurring macromolecules
can also be used to assemble hydrogels in situ. For example,
interactions between glycosaminoglycans (e.g. heparin) and
polymer-grafted peptide sequences extracted from heparin-
binding proteins can be used to rapidly form hydrogels which
exhibit drug release kinetics and degradation profiles related to
the affinity between heparin and the heparin-binding peptide
[59]. Thermally associating synthetic polypeptides can simi-
larly cross-link via hydrophobic domain interactions to yield
hydrogels with high mechanical strength. In this case, assem-
bly is controlled not only by the amphiphilic amino acid
sequences but also by the chain conformations of the assem-
bling polypeptides [60], with polypeptides containing helical
coiledecoil structures giving particularly strong gels [61,62].
Polypeptide-based systems are of interest given their composi-
tional flexibility, enabling precise tuning of the gelation time,
mechanical properties, and degradation time as desired to
control drug release [63].2.2. Covalently cross-linked hydrogelsWhile physically cross-linked hydrogels have the general
advantage of forming gels without the need for chemical mod-
ification or the addition of cross-linking entities in vivo, they
have limitations. Because the strength of a physically cross-
linked hydrogel is directly related to the chemical properties
of the constituent gelators, it is difficult to decouple variables
such as gelation time, network pore size, chemical functional-
ization, and degradation time, restricting the design flexibility
of such hydrogels. In addition, the tissue dwell time of phys-
ically bonded hydrogels is often poor due to dilution followed
by dissipation. In contrast, covalent cross-linking prevents
both dilution of the hydrogel matrix and diffusion of the poly-
mer away from the site of injection.
Many chemistries have been explored for in situ cross-link-
ing hydrogels, the most common of which are summarized inolecular complex between poly(ethylene oxide) (PEO) and cyclodextrin.
Fig. 7. Typical in situ-cross-linking chemistries: (a) reaction of an aldehyde
and an amine to form a Schiff base; (b) reaction of an aldehyde and hydrazide
to form a hydrazone; (c) Michael reaction of an acrylate and either a primary
amine or a thiol to form a secondary amine or a sulfide.
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be added to reactive pre-polymers as small molecules or con-
jugated directly to them.
2.2.1. Small-molecule cross-linking
Small-molecule cross-linkers can be used to produce in situ
cross-linked hydrogels, as illustrated by several recent exam-
ples. Dextranetyramine [64] and hyaluronic acidetyramine
[65] hydrogels have been prepared using horseradish peroxi-
dase and hydrogen peroxide as cross-linkers, with controllable
gelation times ranging from 5 s to 9 min according to the re-
actant concentrations used. Human serum albumin was
cross-linked with the active ester form of tartaric acid to create
a highly tissue adhesive hydrogel capable of controlling doxo-
rubicin release [66]. Periodate-oxidized sodium alginate can
be rapidly cross-linked with proteins such as gelatin in the
presence of low concentrations of sodium tetraborate (borax)
to generate hydrogels which are suitable for delivery of prima-
quine and encapsulation of hepatocytes with minimal cytotox-
icity [67]. Genipin (a naturally derived chemical from
gardenia fruit) has also been found to efficiently cross-link
amino-functionalized pre-polymers into hydrogels while ex-
hibiting minimal toxicity to native tissues. Hydrogels based
on amino-terminated PEG, N,O-carboxymethyl chitosan
[68], gelatin [69], and bovine serum albumin [69] have been
prepared using genipin cross-linking, with dissolution rates
tailorable from 3 min to more than 100 days. The drug itself
may also in some cases be used as the cross-linker. For exam-
ple, primaquine (a di-amino drug) has been used to cross-link
periodate-oxidized gum arabic into a hydrogel via the rapid
formation of Schiff bases between the drug-bound amine
groups and the aldehyde groups in the polymer [70]. This ap-
proach is restricted to cases in which the drug has two reactive
functional groups available for functional group chemistry. Ageneral disadvantage of each of these small-molecule cross-
linking methods is the potential toxicity of residual unreacted
small-molecule cross-linkers. For example, glutaraldehyde is
often used to form carbohydrate-based hydrogels [71] but is
also a tissue fixative.
2.2.2. Polymerepolymer cross-linking
Polymers pre-functionalized with reactive functional
groups avoid the use of potentially toxic small-molecule
cross-linking agents. The main limitation of this approach is
that significant polymer modification chemistry may be re-
quired to prepare the functionalized pre-polymers. In addition,
the pre-gel polymers are often themselves somewhat cyto-
toxic, even when prepared from highly biocompatible polymer
precursors. While this problem is largely mitigated during gel
formation due to the rapidity of cross-linking and the multiple
functional groups attached to each polymer precursor (reduc-
ing the probability of unreacted residual polymers), such tox-
icity could become problematic as the polymer degrades to
form potentially tissue-reactive oligomers.
Several types of linkages can be made depending on the de-
sired speed of cross-linking and biodegradability of the result-
ing conjugates. The formation of a hydrazone bond e an
asymmetric Schiff base e via the reaction of an aldehyde
and a hydrazide facilitates rapid cross-linking of gel precur-
sors [72]. We have used hyaluronic acid cross-linked by hydra-
zone bonds to provide prolonged-duration local anesthesia
[73] and to control the release of tissue plasminogen activator
[74] and budesonide [74] to the peritoneum. Similar ap-
proaches have been used to design hydrogels based on dextran
[75], poly(vinyl alcohol) [76] and poly(aldehyde guluronate;
an oxidized alginic acid derivative) [77]. The latter has been
used as an injectable matrix for the effective delivery of osteo-
blasts and growth factors [77].
Michael addition between a nucleophile (i.e. an amine or
a thiol) and a vinyl group is another widely investigated in
situ cross-linking chemistry which is particularly useful for
in situ cross-linking hydrogels due to its rapid reaction time,
its flexibility in forming multiple types of bonds, and the rel-
ative biological inertness of the polymeric precursors. Michael
addition has been used to cross-link vinyl sulfone-functional-
ized dextrans with thiolated poly(ethylene glycol), with gel
formation occurring over 0.5e7.5 min according to the prop-
erties of the functionalized polymers [78]. A PEG diacrylate
can be used to cross-link dithiolated PEG [79] or thiolated nat-
ural polymers including hyaluronic acid, chondroitin sulfate,
and gelatin [80] with gelation times ranging from 2 to 6 min
[80]. As an example, a mixture of thiol-modified heparin
and thiol-modified hyaluronic acid can be gelled with PEG di-
acrylate to form a hydrogel which can prolong the release of
basic fibroblast growth factor in vivo [81]. A thiolated peptide
has also been used to cross-link methacrylated hyaluronic acid
using the same chemistry, although reported gelation times ex-
ceeded 30 min [82]. Efficient design of Michael addition
cross-linked hydrogels is further facilitated by the develop-
ment of kinetic modeling approaches for predicting the rates
of hydrogel formation and degradation [83] and/or the release
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the hydrogel network [84]. Such model approaches have con-
siderable potential for the bottom-up design of future drug
delivery vehicles.
Other types of injectable hydrogel delivery strategies have
been reviewed comprehensively elsewhere [85e87]. Many
have yet to be evaluated for drug delivery and may offer addi-
tional advantages compared to current chemistries. The sim-
pler the process in terms of chemistry and the need for
accessory equipment, the better.
Although the preceding discussion focused on the potential
toxicity of various cross-linking approaches, both local and
systemic toxicity can also arise from the rapid release of the
drug payload itself. For example, local tissue injury from
cross-linked hyaluronic acid hydrogels containing the local
anesthetic bupivacaine was entirely due to the drug [88].
This could also be an issue with the release of macromolecules
such as proteins. However, drug toxicity is neither specific to,
nor acutely more problematic in, hydrogel-based systems
compared to other drug delivery approaches.2.3. Optimization of in situ gelling hydrogelsSuccessful optimization of injectable hydrogels must con-
sider several factors. The concentration of the polymers used
to prepare the gel influences both the diffusion-based drug re-
lease kinetics and the degradation time of the hydrogel. How-
ever, the concentration of polymers or their functionalized
derivatives is often limited by the aqueous solubility of the
gel precursors or the resulting high viscosity of the solutions,
although the concentration can be increased when lower mo-
lecular weight gel precursors are used. The rate of in situ
cross-linking is determined by the underlying chemical kinet-
ics of the cross-linking reaction, the ease of diffusion of the
polymer precursors through the partially viscous pre-gel solu-
tion, and the concentration of polymers used to prepare the hy-
drogel. Different rates of gelation may be desirable in different
applications. Fast-gelling formulations may be advantageous
in surgical settings and may entrap drugs more effectively to
delay release; slower-gelling formulations may give the mu-
coadhesive pre-polymers time to penetrate the surrounding tis-
sues and enhance bioadhesion. The cross-linking density in the
hydrogels can be controlled by the amount of small-molecule
cross-linker added and/or the density of reactive functional
groups on the gel precursors. Higher cross-linking densities re-
sult in hydrogels with smaller mesh sizes, thereby reducing the
release rate of entrapped drugs; however, the high degree ofFig. 8. Physical (a) and chemical (b) strategies for enhancing the interactchemical modification required to form gels with high cross-
link densities can significantly alter the physical properties
of the base hydrogel, particularly in terms of the drugehydro-
gel affinity or mechanical strength of the gel. Thus, trade-offs
must be made in the hydrogel design according to the targeted
application of the drug-eluting hydrogel.
Applying in situ gelling hydrogels can be awkward clini-
cally. The interacting or reactive gel precursors may have to
be kept separate prior to injection by use of a double-barreled
syringe or some other device. Depending on the gelation time,
injection may have to be done in haste as the needle may be-
come clogged as the polymers heat up or react. This may pre-
vent injection of part of or all of the gel, a major problem
particularly if the placement of the needle itself was difficult.
Triggered release of the cross-linker in vivo may help to ad-
dress this problem. For example, liposomes are designed to
rupture at physiological temperature and release calcium
ions effectively cross-linked aqueous sodium alginate via ionic
interactions and fibrinogen via the in situ activation of a
calcium-dependent transglutaminase enzyme [89].
3. Extending the effectiveness of hydrogels for drug
delivery
The high water content of most hydrogels typically results
in relatively rapid release of drugs from the gel matrix over the
period of hours or days, particularly in the case of hydrophilic
drugs for which hydrogel delivery is typically applied. This re-
lease profile is much shorter than those which can be achieved
using microspheres or macroscopic devices based on more hy-
drophobic polymers (for example, PLGA). In response, a range
of strategies have been explored to reduce the release rate of
drug from hydrogels. These strategies can be categorized by
whether they enhance the interactions between the drug and
the hydrogel matrix and/or increase the diffusive barrier to
drug release from the hydrogel.3.1. Drugehydrogel interactionsBoth physical and chemical strategies can be employed to
enhance the binding between a loaded drug and the hydrogel
matrix to extend the duration of drug release, as illustrated
schematically in Fig. 8.
3.1.1. Physical interactions
Charge interactions between ionic polymers and charged
drugs have frequently been employed to increase the strengthion between a loaded drug and a polymeric gel to slow drug release.
Fig. 9. Formation and structure of semi- and full interpenetrating polymer
networks (IPN).
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drug release. Phosphate-functionalized polymers are effective
because of their multivalent anionic charge. Phosphate-con-
taining soft contact lenses can bind the cationic drug naphazo-
line in quantities directly proportional to the phosphate content
[90]. Similarly, the uptake of cationic lysozyme into N-isopro-
pylacrylamide-based hydrogels functionalized with poly-
oxyethyl phosphate-containing comonomer is significantly
enhanced compared to non-functionalized PNIPAM hydrogels
[91]. Amino functional groups can similarly be applied to de-
lay the release of anionic drugs. For example, copolymeriza-
tion of 4-vinylpyridine or N-(3-aminopropyl)methacrylamide
increased the loading of NSAIDs into a poly(hydroxyethyl
methacrylate) hydrogel by more than one order of magnitude
and prolonged drug release up to 1 week without changing the
mechanical properties of the network [92].
Both anionic and cationic functional groups typically found
in carbohydrate-based polymers can have significant effects on
prolonging the release of a drug of opposite charge [93].
Amino acid-modified gelatin hydrogels slow down the release
of lysozyme and trypsin inhibitor protein to an extent directly
proportional to the strength of the charge interactions between
the amino acid chain and the entrapped proteins [94]. Charge
interaction has also been cited as one of the reasons for using
hyaluronic acid as a delivery vehicle for local anesthetics, the
others being viscosity and biocompatibility [95]. Hyaluronic
acid is anionic, while most local anesthetics are cationic in
aqueous solution. However, the literature regarding the use
of hyaluronic acid with local anesthetics shows a range of re-
sults, from marked [96] or modest [95] prolongation of effect
to none [97]. This variability is likely due to differences in
formulation (concentration, molecular weight, viscosity) and
animal model which may affect the effectiveness of chargee
charge interactions for prolonging drug release.
As an alternative, monomers or polymers with specific non-
ionic affinities to particular drugs can be copolymerized into
hydrogels to delay or enhance the release of drugs. The anti-
fungal drug amphotericin B has a strong interaction with
photocross-linked dextran-based hydrogels, allowing contact
killing of fungi for 2 months [98]. Amphotericin B did not
bind to PEG-derived hydrogels of the same chain density.
The exact molecular binding mechanism remains unclear.
3.1.2. Covalent bonding
Drugs can also be covalently conjugated to the hydrogel
matrix such that their release is primarily controlled by the
rate of chemical or enzymatic cleavage of the polymeredrug
bond. For example, dexamethasone has been conjugated to
a photoreactive mono-acrylated PEG through a degradable
lactide bond to facilitate osteogenic differentiation of human
mesenchymal stem cells [99], and daunomycin cross-linked
to poly(aldehyde guluronate) was released over periods rang-
ing from 2 days to 6 weeks according to the hydrolysis rate
of the drugepolymer covalent linkage [100]. Alternately,
drug release may be regulated via the hydrolysis of the polymer
backbone, possibly inducing the release of a partially modi-
fied drug analogue. For example, methacrylic-functionalizednon-steroidal anti-inflammatory drugs have been conjugated
to methacrylic-functionalized dextrans via UV irradiation;
a chemically modified drug analogue is released as the dextran
hydrogel degrades [101]. The cross-linker can be engineered
to give specific durations of release. For example, by changing
the length of a sulfide-based cross-linker from three to four
carbons, the time required to release bound paclitaxel from
a hydrogel was increased from approximately 4 days to 2
weeks [102].3.2. Gel network engineeringSeveral approaches have been explored to control the diffu-
sion of drugs out of hydrogel matrices by modifying the
microstructure of the hydrogel, either throughout the full gel
network or locally at the hydrogel surface. A simple method
of performing such modifications is to increase the percentage
of cross-linking monomer incorporated into the gel. However,
highly cross-linked gels exhibit very slow responses to envi-
ronmental stimuli and may possess undesirable mechanical
properties. As a result, more sophisticated strategies may be
required.
3.2.1. Interpenetrating polymer networks (IPNs)
An interpenetrating polymer network is formed when a
second hydrogel network is polymerized within a pre-poly-
merized hydrogel. This is typically done by immersing
a pre-polymerized hydrogel into a solution of monomers and
a polymerization initiator. IPNs can be formed either in the
presence of a cross-linker to produce a fully interpenetrating
polymer network (full IPN) or in the absence of a cross-link-
ing mechanism to generate a network of embedded linear
polymers entrapped within the original hydrogel (semi-IPN),
as illustrated in Fig. 9. The main advantages of IPNs are
that relatively dense hydrogel matrices can be produced which
feature stiffer and tougher mechanical properties, more widely
controllable physical properties, and (frequently) more effi-
cient drug loading compared to conventional hydrogels.
Drug loading is often performed in conjunction with the poly-
merization of the interpenetrating hydrogel phase [103].
Fig. 11. ‘‘Plum pudding’’, composite hydrogels containing drug encapsulated
in a secondary controlled release vehicle (e.g. microparticles, nanoparticles,
microgels, liposomes, micelles). D1 and D2 represent the diffusion coefficients
of drug out of the hydrogel (D1 ¼ release from secondary release vehicle;
D2 ¼ diffusion through hydrogel).
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trolled to tune the drug release kinetics, the interactions be-
tween the hydrogel and the tissues, and the mechanical
properties of the gel [104]. Interpenetrating phases with differ-
ent degradation profiles and/or different swelling responses to
physiological conditions can be used to provide multiple con-
trols over the swelling responses of hydrogels and thus the po-
tential drug release kinetics [105]. IPNs can also moderate the
effect of environmental changes on hydrogel responses and
burst drug release because of their ability to restrict the equi-
librium swelling of either or both of the interpenetrating
phases according to the elasticity (i.e. cross-linking density)
of either or both gel phases. For example, a highly cross-linked
interpenetrating network of a pH-sensitive hydrogel and a hy-
drolysable hydrogel restricts the typically rapid swelling
response of a pH-swelling hydrogel to facilitate linear swell-
ing profiles following an abrupt pH change from pH 7.4 to 2
[106]. Such responsivity is particularly suitable for minimiz-
ing burst release of drugs in oral drug delivery applications.
As another example, a lightly cross-linked chitosanePNIPAM
interpenetrating network significantly increased the loading
capacity of diclofenac compared to a pure PNIPAM hydrogel
while maintaining the sharp thermosensitivity of the PNIPAM
phase to regulate the release kinetics [107].
Semi-IPNs can more effectively preserve rapid kinetic re-
sponse rates to pH or temperature (due to the absence of a re-
stricting interpenetrating elastic network) while still providing
most of the benefits of IPNs in drug delivery (e.g. modifying
pore size, slowing drug release, etc.). For example, entrapping
linear cationic polyallylammonium chloride in an acrylamide/
acrylic acid copolymer hydrogel imparted both higher me-
chanical strength and fully reversible pH switching of theoph-
ylline release [108].
3.2.2. Surface diffusion control
As an alternative to changing the bulk structure of a hydro-
gel, surface-specific modifications can be performed to gener-
ate a reduced-permeability ‘‘film’’ layer at the hydrogel
surface, often in conjunction with a thermosensitive switch
for oneoff drug release. Drug diffusion control via this mech-
anism is illustrated in Fig. 10. By this mechanism, thermosen-
sitive PNIPAM polymers can be grafted onto the surface of
hydrogels to provide temperature-dependent surface perme-
ability and thus release kinetics [109]. Drug release is rapid
at low temperatures but is significantly slowed at higher tem-
peratures as the thermosensitive polymer undergoes a phaseFig. 10. Drug diffusion control by surface-modifying a hydrtransition and collapses onto the hydrogel surface. Alternately,
a drug-loaded hydrogel can be coated with a dense polyelec-
trolyte multilayer film [110], limiting drug diffusion out of
the bulk hydrogel. The rate of diffusion can be designed to
be dependent on the pH of the medium, the degradation rate
of the film, or the environmentally controlled swelling state
of the coated hydrogel, which can exert mechanical pressure
on the coating to cause film rupture and thus burst drug release
at a targeted condition [111].
3.2.3. Composite hydrogels
Microspheres, liposomes, and other types of particle-based
drug delivery vehicles have proven capacity for long-term re-
lease. As a result, growing interest has focused on overcoming
the inherent pharmacological limitations of hydrogels by co-
formulating particulate systems into the hydrogel matrix to
form composite or ‘‘plum pudding’’ hydrogel networks, as
illustrated in Fig. 11.
The formation of composite hydrogel drug release vehicles
may increase the biocompatibility of the particulate vehicle by
‘‘hiding’’ the microparticles within the hydrogel while also
preventing microparticle migration away from their targeted
site in vivo. Poly(lactic-co-glycolic acid) nanoparticles can
be incorporated within a cross-linkable hyaluronan-based hy-
drogel matrix without compromising the biocompatibility or
anti-adhesion properties of the hyaluronic acid carrier [112],
facilitating the incorporation of a wider array of anti-adhesion
drugs within the matrix. The hydrogel phase may also improve
the kinetic release profile of microspheres by providing an
additional diffusion barrier to drug release, moderating or
eliminating the burst release typically observed with micro-
spheres and extending release of drugs [9,73].ogel with an environmentally-responsive polymer graft.
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the particle entrapment matrix. For example, PLGA micropar-
ticles entrapped in a reverse thermally gelled PNIPAM-g-chi-
tosan matrix released 5-fluorouracil with minimal burst and
near zero-order release kinetics [23], poloxamer 407 has
been used to extend the duration of nerve blockade from lido-
caine-containing microparticles by a few hours [9], and PLGA
particles entrapped in a poly(vinyl alcohol) hydrogel achieved
approximately zero-order release of dexamethasone over a
period of 1 month [113].
Liposomes can also be entrapped in hydrogels. Liposomes
entrapped in carbopol and hydroxyethylcellulose-based
hydrogels can control the release of calcein and griseofulvin
according to the rigidity of the liposomal membrane [114],
while liposomes entrapped in poly(hydroxyethyl methacrylate)
hydrogels mimicking contact lenses can control the release of
anti-glaucoma drugs for up to 8 days [115]. In situ gelling,
physically cross-linked hydrogels can also be prepared to entrap
liposomes. When a poly(N-isopropylacrylamide) solution is
mixed with liposomes surface-functionalized with a copolymer
of NIPAM and octadecylacrylate, a physically cross-linked gel
can be formed at temperatures in excess of 30 Cwhich exhibits
increasing drug release with increasing temperature [116].
The microparticles entrapped within the hydrogel can
themselves be gel-based (microgels). For example, gelatin
microparticles entrained in a thermal-gelling poly(ethylene
glycol fumarate) matrix delivered TGF-beta 1 for cartilage
tissue repair [117]. As with other particle types, multiple
types of gel microparticles can be entrapped in the same hy-
drogel matrix to deliver multiple drug payloads; for example,
an N-isopropylacrylamideeN-tert-butylacrylamide (NIPAMe
BAM) microgel can deliver pyrene while a NIPAMeBAMe
acrylic acid copolymer microgel can deliver rhodamine B at
controllable rates [118]. Microgels can also be cross-linked di-
rectly, without an encapsulating bulk hydrogel phase, to form
a hierarchal gel network which permits dual tuning of drug re-
lease and degradation according to the structure and composi-
tion of the individual microgel particles and the density and
cross-linking chemistry of the macroscopic nanoparticle net-
work [35].
Surfactant-stabilized microemulsion droplets [119], surfac-
tant micelles [93], and polymeric micelles [120] can similarly
be entrapped in hydrogel networks to provide prolonged drug
release. Polymeric micelles based on block copolymers have
particular promise due to their lower toxicity given the absence
of small-molecule surfactants or organic solvents. For example,
poly(N-isopropylacrylamide)-block-poly(methyl methacrylate)
micelles entrapped inside a poly(N-isopropylacrylamide) hy-
drogel can release prednisone acetate in a controlled manner
according to the temperature of the thermosensitive hydrogel
network [121].
4. Expanding the range of drugs amenable to hydrogel-
based delivery
Classically, hydrogels have been used to deliver hydro-
philic, small-molecule drugs which have high solubilities inboth the hydrophilic hydrogel matrix and the aqueous solvent
swelling the hydrogel. In this case, it is relatively simple to
load a high quantity of drug into a swollen hydrogel by simple
partitioning from a concentrated aqueous drug solution and
subsequently release the hydrophilic drug payload into an
aqueous environment. However, this process is relatively inef-
ficient in the case of large macromolecular drugs (e.g. pro-
teins, nucleic acids, etc.) which have diffusive limitations to
their partitioning into a hydrogel phase or hydrophobic drugs
which are sparingly soluble in both the aqueous and the hydro-
gel phases. Both of these classes of drugs, however, are
becoming increasingly important clinically as a result of im-
proved understanding of the molecular basis of disease and
the more frequent application of molecular design approaches
for small-molecule drug design. Macromolecular drug uptake
is typically restricted by the diffusion of the macromolecular
drug payload through the hydrogel network and thus can be
addressed at least partially by engineering the pore size of hy-
drogels, as described in Section 3.2. Hydrogel-based hydro-
phobic drug delivery is in many respects a more difficult
problem given the inherent incompatibility of the hydrophilic
hydrogel network and the hydrophobic drug. Thus, the prob-
lem of hydrophobic drug delivery is two-fold: how to load
the hydrophobic drug into the gel matrix and, once present,
how to effectively release the drug into the aqueous gel
environment.
A variety of strategies have been used to improve hydro-
phobic drug loading into hydrogels. One simple approach is
to form a solid molecular dispersion of a poorly soluble
drug, exploiting the enhanced solubility of many hydrophobic
compounds in the amorphous state rather than the crystalline
state [122]. By this strategy, drugs are loaded into hydrogels
in an appropriate solvent and bind strongly to the polymer
chains in the hydrogel via hydrogen bonding interactions, pre-
venting drug re-crystallization when the hydrogels are exposed
to water and enhancing release of the hydrophobic drug. How-
ever, drug re-crystallization typically occurs over time, limit-
ing the commercial use of solid molecular dispersions. Any
of the composite hydrogel strategies outlined in Section
3.2.3 could be useful for hydrophobic drug delivery. However,
such systems can be complex to fabricate and deliver. Instead,
a variety of strategies for introducing hydrophobic domains di-
rectly into otherwise hydrophilic hydrogel networks have per-
mitted significant improvements in the loading of hydrophobic
drugs. These basic strategies are illustrated schematically in
Fig. 12 and are reviewed below.4.1. Incorporation of hydrophobic sitesThe most common approach for generating hydrophobic
domains within hydrogels is the copolymerization with hydro-
phobic comonomers, introducing statistically distributed hy-
drophobic sites within the networks. This strategy introduces
binding sites for hydrophobic drugs and condenses the bulk
dimensions of the gel, reducing the average pore size and
slowing diffusion-limited release. In one approach, n-(meth)-
acrylate esters of varying chain lengths are copolymerized
Fig. 12. Strategies for hydrophobic drug delivery via hydrogels (a) random copolymerization of a hydrophobic monomer; (b) grafting of hydrophobic side-chains;
(c) incorporation of cyclodextrin.
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cross-linkers (e.g. azobenzenes [123]), to achieve the hydro-
phobic modification. For example, copolymerization of acrylic
acid-2-ethylhexyl ester in a methacrylic acid-based hydrogel
improves the loading of p-hydroxyanisole and extends its re-
lease from the hydrogel independent of pH [124]. Fluorine-
containing polymers can also be applied as the hydrophobic
modifier. For example, a copolymer gel of N,N-dimethacryl-
amide and 2-(n-ethyl-perfluorooctanesulfonamido) ethyl
acrylate prolongs the release of the ocular antihistamine
pheniramine maleate [125]. Hydrophobic macromonomers
can also be incorporated into hydrogels. For example, a copoly-
mer of allyl-functionalized dextran and poly(lactide) diacrylate
macromonomer increased indomethacin loading and could
control the release rate of indomethacin according to the rate
of poly(lactide) degradation [126].
More recently, molecular design approaches have been ap-
plied to maximize the affinity of a polymer-bound hydropho-
bic domain for a particular drug target while minimizing the
non-specific binding of other hydrophobic compounds in the
gel environment. Bulk screening of a range of different small
molecules with hydrophobic binding properties can identify
those which bind most strongly to a given drug. For example,
paclitaxel loading can be improved 700-fold over its aqueous
solubility when a self-assembled hydrogel of linear polymers
based on picolylnicotinamide (identified as an optimum pacli-
taxel binder via a bulk screening process) was used as the
drug-eluting hydrogel [127].
Alternately, hydrogel networks can be modified to generate
hydrophobic domains with more localized and controllable
distributions. Hydrophobic side chains can be grafted onto
the polymer precursors which can self-assemble to form hydro-
phobic domains within the bulk hydrogel network and bind hy-
drophobic drugs; this approach has been demonstrated with
octyl-modified carboxymethylpullulan [128]. Semi-interpene-
trating networks can also be prepared by entrapping a partiallyhydrophobic hydrogel phase (i.e. PEGePCL diacrylate macro-
mer) within a hydrophilic precursor hydrogel (hydroxypropyl
guar gum), improving the mechanical properties of the hydro-
gel while prolonging the release of bovine serum albumin
[129]. Similarly, the entrapment of poly(ethyl acrylate) in
a functionalized poly(N-isopropylacrylamide) matrix slowed
the release of daidzein and significantly moderated the burst re-
lease of drug typically observed from PNIPAM matrices [130].4.2. CyclodextrinsThe main problems with rendering the hydrogel hydropho-
bic via grafting, copolymerization, or IPN-based approaches
are the significant hydrogel deswelling and delocalized surface
and bulk hydrophobicity which are introduced into the gel net-
work, potentially reducing the biocompatibility and/or the low
protein binding properties of hydrogels. Cyclodextrins are of
interest in this context given their hydrophilic exterior, which
is useful for maintaining the bulk hydrophilicity and swelling
state of the hydrogel, and their hydrophobic interior, which
can facilitate the entrapment and controlled release of hydro-
phobic drugs. Cyclodextrin-containing hydrogels can be
prepared in many ways. Most simply, preformed cyclodex-
trinedrug complexes can be loaded into the hydrogel after
[131] or during [132] gel cross-linking. However, this strategy
may result in the diffusion of the drugecyclodextrin inclusion
complex out of the hydrogels, leading to non-optimal control
over release kinetics. Grafting cyclodextrin to the hydrogel
provides improved control over drug release kinetics. Copoly-
merization of a vinyl monomer (acrylic acid [133], N-isopro-
pylacrylamide [134], or 2-hydroxyethyl acrylate [135]) with
an acrylamidomethyl- or acryloyl-functionalized cyclodextrin
can facilitate the loading and release of triamcinolone aceto-
nide [133], ibuprofen [134], or melatonin [135]. Alternately,
cyclodextrins can be cross-linked directly using digylcidyl-
ethers to form a hydrogel. This strategy improved the loading
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by simple aqueous partitioning into hydrogels of similar com-
position and water contents and resulted in release of a thera-
peutic level of drug for up to a week [136].
5. Conclusion and future perspective
Significant progress has been made in improving the prop-
erties of hydrogels used for drug delivery and expanding the
range of drugs and kinetics which can be achieved using a
hydrogel-based delivery vehicle. However, several challenges
remain to improve the clinical applicability of hydrogels for
drug delivery.
One set of major challenges relates to improving the ease of
clinical usage. Designing physical gelators which gel at lower
polymer concentrations and at more precise gelation tempera-
tures would reduce the risk of premature gelation inside the
needle upon injection. Similarly, for covalently cross-linked
hydrogels, the further development of strategies to release
cross-linker in a triggered manner inside the body would min-
imize the risk of syringe clogging, improve the localization of
cross-linker release to minimize in vivo toxicity, and enable
mixing of the chemically reactive gel precursors in a single
syringe, eliminating the need for double-barreled syringes.
Improvements in this domain could also be achieved by devel-
oping better applicator systems for the hydrogels. The applica-
tion of new physicochemical strategies (or combinations of
existing cross-linking techniques) to simultaneously control
not only the gelation process but also the interactions between
the gel and the native tissues would further expand the utility
of injectable hydrogels for both drug delivery and tissue engi-
neering-based applications.
There are also persistent challenges in expanding the types
of kinetic release profiles which can be achieved using hydro-
gels. Extending the duration of release would be useful in
many applications and could allow hydrogels to supplant hy-
drophobic systems for long-term release applications. This
would be beneficial because of the better biocompatibility of
hydrogels. The development of hydrogel-based systems where
the rate of drug delivery could be easily modulated oneoff
over time could also be of benefit for applications requiring
varying doses of a drug over time (e.g. delivery of insulin or
analgesics). Hydrogels with different degradation profiles
and/or environmentally responsive segments may help to
address these kinetic issues.
There is a need for continued improvement in the delivery
of not only hydrophobic molecules, but also the delivery of
more sensitive molecules such as proteins, antibodies, or nu-
cleic acids which can readily be deactivated or unfolded by
interactions with the hydrogel delivery vehicle. This is a partic-
ular issue with in situ cross-linking hydrogels, in which the hy-
drophobic domains formed in thermal, physically gelling
polymers or the functional group chemistry used to form cova-
lently gelling hydrogels can significantly affect the biological
activity of the entrapped biomolecule. Pre-encapsulation or
complexation of biomolecules prior to in situ-hydrogel forma-
tion may help to address this issue.Progress on any or all of these challenges would greatly ex-
pand the potential of hydrogel-based drug delivery to success-
fully deliver the next generation of designed drugs at the
desired rate and location in the body. In addition, there are
many broad and niche applications not covered in this review
where there is ample room for progress. As in many branches
of drug delivery, it is likely that ‘‘convergence’’ [137] e the
merging of once disparate fields of science e will guide the
future development of drug-eluting hydrogel design.
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